ADAP Valuation

Adaptimmune Therapeutics PLC

Add to Watchlist

Advanced Chart

0.290

+0.017(6.225%)1D

Overview
Forecast
Valuation
Earnings

ADAP Relative Valuation

ADAP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADAP is overvalued; if below, it's undervalued.

Historical Valuation

Adaptimmune Therapeutics PLC (ADAP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.25 is considered Undervalued compared with the five-year average of -3.74. The fair price of Adaptimmune Therapeutics PLC (ADAP) is between 1.90 to 2.62 according to relative valuation methord. Compared to the current price of 0.29 USD , Adaptimmune Therapeutics PLC is Undervalued By 84.73%.

Relative Value

Fair Zone

1.90-2.62

Current Price：0.29

84.73%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-1.98

P/B

Median3y

3.23

Median5y

2.91

-151.74

FCF Yield

Median3y

-61.31

Median5y

-40.50

Competitors Valuation Multiple

The average P/S ratio for ADAP's competitors is 29.75, providing a benchmark for relative valuation. Adaptimmune Therapeutics PLC Corp (ADAP) exhibits a P/S ratio of 1.25, which is -95.80% above the industry average. Given its robust revenue growth of 28.30%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ADAP.O

Adaptimmune Therapeutics PLC

1.25

Average P/S: 29.75

28.30%